Boston Scientific saw its IBD SmartSelect Composite Rating rise to 96 Wednesday, up from 94 the day before.
The revised score means the stock currently tops 96% of all other stocks in terms of key performance metrics and technical strength.
Boston Scientific is trading within a buy range from a 91.93 entry from a flat base.
Looking For The Best Stocks To Buy And Watch? Start Here
The stock sports a 93 EPS Rating, which means its recent quarterly and longer-term annual earnings growth tops 93% of all stocks.
Its Accumulation/Distribution Rating of B- shows moderate buying by institutional investors over the last 13 weeks.
In Q3, the company posted 26% EPS growth. Sales growth rose 19%, up from 14% in the prior quarter. That marks one quarter of accelerating revenue growth.
Boston Scientific earns the No. 3 rank among its peers in the Medical-Products industry group. Globus Medical is the No. 1-ranked stock within the group.
